Related Experiment Video
Updated: Aug 19, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Research Advances on the Molecular Structural Basis and Mechanisms of Quercetin and Its Derivatives in Improving
Qichang Xing1, Jia Chen1, Renzhu Liu1
1Department of Clinical Pharmacy, The Central Hospital of Xiangtan (The affiliated hospital of Hunan University), Xiangtan, Hunan, People's Republic of China.
Abstract:
Insulin resistance is a core pathological link in metabolic diseases such as type 2 diabetes, and its prevention and treatment are current research hotspots. Quercetin, a natural flavonoid, has significant potential to improve insulin resistance through its anti-inflammatory, antioxidant, and metabolic regulatory activities. This review systematically examines literature published between 2020 and 2025 from the PubMed, Web of Science, and Scopus databases, focusing on original mechanistic studies in cellular and animal models of insulin resistance. Our synthesis reveals two mechanistic clusters: quercetin directly activates insulin signaling via the insulin receptor substrate 1/Phosphatidylinositol 3-kinase /Protein Kinase B pathway, enhances muscle glucose uptake through AMP-activated protein kinase-dependent glucose transporter 4 translocation. Indirect mechanisms include gut microbiome modulation with increased short-chain fatty acid production, suppresses hepatic inflammation and targeting of transcription factors. Critically, a clear efficacy hierarchy among derivatives was identified: glycosides show superior bioavailability compared to the aglycone, while methylated derivatives exhibit enhanced stability but divergent effects on peroxisome proliferator-activated receptor γ signaling. Major unresolved challenges include the low oral bioavailability of quercetin aglycone, the lack of systematic structure-activity relationship models, and the absence of rigorous human trials. The review concludes that chemical derivatization and advanced delivery systems offer promising strategies, but clinical translation requires an integrated framework combining systematic structure-activity profiling, mechanistic target selection, and validated human studies.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin: The Receptor and Signaling Pathways
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes II: Pathophysiology